Margaret Foti: The success of synthetic lethality-based treatments highlights the value of basic and translational science

Margaret Foti shared a post by AACR on X, adding:

“The success of synthetic lethality-based treatments highlights the value of basic and translational science, as our understanding of cellular pathways is leveraged to benefit cancer patients. This conference will showcase the latest advances in this critical field.”

Quoting AACR’s post:

“The AACR Special Conference on Expanding and Translating Cancer Synthetic Vulnerabilities will convene this evening with an opening keynote from William R. Sellers. The next three days will highlight the techniques and tools behind this novel treatment strategy.”

Source: Margaret Foti/X and AACR/X

Margaret Foti is the CEO of the American Association for Cancer Research (AACR). Under her leadership, AACR membership has grown from about 3,000 members to over 54,000 in 131 countries and territories, and the AACR’s portfolio of peer-reviewed scientific journals has increased from one to ten.

Foti is one of the most influential voices in advancing the field of cancer research, both in the United States and abroad. In 2007, the AACR established the first AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, which is given annually in her name.